Thu, Sep 18, 2014, 8:44 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Jun 5, 2013 11:27 AM Flag

    11:30 presentation

    Jeffries conference. Thomas Wei, an excellent biotech analyst has been a strong supporter.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Dan said something to the effect of...they can reach proof of concept with 3 wholly-owned compounds before they even need to think about the need for additional financing. That sounded positive regarding the potential for near term dilution, but he has said similar things before. He said 901 enrollment was progressing well, but data in 2014, so the slow play on this continues and maybe that's the reason for additional selling. 289 sounds very exciting, if they can get in gear. Overall, Junius sounds tired from long days at ASCO. IMGN broke recent support, looks to be heading lower, but I think (hope) the people looking to buy at $15 will not get filled. IMGN always goes higher and mostly lower than I expect, so maybe it will happen. Looks like a buyable dip here and now, good luck traders!

 
IMGN
11.34+0.04(+0.35%)Sep 18 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.